Insider Buying: Cosmos Health (NASDAQ:COSM) CEO Purchases 766,284 Shares of Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas purchased 766,284 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was acquired at an average price of $0.18 per share, with a total value of $137,931.12. Following the purchase, the chief executive officer directly owned 14,248,092 shares in the company, valued at $2,564,656.56. This represents a 5.68% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Grigorios Siokas also recently made the following trade(s):

• On Thursday, June 11th, Grigorios Siokas acquired 218,447 shares of Cosmos Health stock. The stock was acquired at an average price of $0.21 per share, for a total transaction of $45,873.87.
• On Wednesday, June 10th, Grigorios Siokas acquired 701,447 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.23 per share, with a total value of $161,332.81.

Cosmos Health Price Performance

COSM traded up $0.03 on Thursday, hitting $0.21. 3,351,799 shares of the company’s stock traded hands, compared to its average volume of 4,598,194. The company’s 50 day simple moving average is $0.23 and its 200-day simple moving average is $0.33. The firm has a market cap of $12.49 million, a price-to-earnings ratio of -0.32 and a beta of 4.83. Cosmos Health Inc. has a one year low of $0.16 and a one year high of $1.32. The company has a current ratio of 1.08, a quick ratio of 0.92 and a debt-to-equity ratio of 0.31.

Cosmos Health (NASDAQ:COSM) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The business had revenue of $18.40 million during the quarter, compared to analyst estimates of $17.93 million. Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. As a group, research analysts anticipate that Cosmos Health Inc. will post 0.01 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd grew its holdings in shares of Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after purchasing an additional 34,117 shares in the last quarter. Renaissance Technologies LLC raised its stake in Cosmos Health by 16.7% during the first quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock valued at $124,000 after purchasing an additional 55,925 shares in the last quarter. Finally, Citadel Advisors LLC lifted its position in Cosmos Health by 133.1% during the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after purchasing an additional 128,776 shares during the last quarter. 12.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cosmos Health in a report on Monday, June 15th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.